Wednesday, August 10, 2022


FDA Grants Extension of Shelf-life & Expiration Date for GenBody COVID-19 Ag Test

Latest Posts

New Study Highlights Superior Efficacy of At-home Dry EEG assessment Compared to Lab-based Monitoring

Results indicate that easy-to-use task-driven EEG can yield clinical-grade data in large-scale, real-world investigations in neuroscience with extremely high adherence rates.

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

“We are excited to further advance the development of GDA-201, a NAM-enabled natural killer (NK) cell therapy candidate which we believe has the potential to be a new readily available, cryopreserved treatment option for cancer patients with relapsed/refractory lymphoma,” said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell.

Akadeum Life Sciences Announces New Dead Cell Removal Kit Using Microbubble Technology

Akadeum Life Sciences advises that the new buoyant separation method creates a more effective way for researchers to use valuable samples with a higher retention rate of viable cells than current magnetic techniques.

Bio-Rad Extends Range of StarBright Violet and UltraViolet Dyes for Multiplex Flow Cytometry

StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 dyes conjugated to highly validated antibodies for multicolor panel design in immunology research.

GenBody America, LLC, the U.S. affiliate of GenBody, Inc., a South Korean manufacturer of rapid diagnostic tests and reagents for point-of-care applications for COVID-19, today announced that the FDA has granted an extension of the shelf-life for its COVID-19 Ag test from 12 months to 21 months when stored at 2° – 30° C (approx. 35° – 86° F).

This extension was granted after FDA review of long-term studies demonstrating that the GenBody tests maintain their performance long after the initially defined 12-month window.

“As the public fatigues from COVID-19, and as preventative measures and guards are lowered when it comes to travel and in-person gatherings, we believe it’s still extremely important for people to invest in reliable and regular rapid testing to safeguard themselves, their employees, and their family members,” said David Yoo, CEO & founder of Genbody America. “This FDA extension reassures our customers that they will have access to viable rapid tests now and through any upcoming surge that is likely to occur as new variants emerge and flu season sets in.”

More than two years into the pandemic, it has become increasingly clear that the COVID-19 virus is here to stay and will continue to impact global health, economies, and protocols well into the future, especially if not properly mitigated and managed. For that reason, ongoing access to testing is still a crucial element of prevention, and GenBody America wanted to ensure the public has access to as many tests as possible ahead of the colder months, flu seasons, and holiday travel schedules that created widespread test shortages in past years.

With this extension from the FDA, customers and end users of GenBody America’s antigen tests can be confident that any test purchased from GenBody which remains in inventory will continue to be reliable and stable for use with an extended shelf-life window of 21 months, as an uptick in positive cases is projected in the coming months.

“Ensuring the consistent performance of the GenBody test device over time is critical,” said Dr. Andrew Kim, Chief Medical Officer of GenBody America. “The studies submitted to FDA are performed over a range of storage conditions and temperatures and have demonstrated no decrease in performance over 21 months, which can provide assurance to the user of test quality and stability.”

GenBody tests have been validated in multiple independently run clinical trials, most recently at Emory University. Ongoing studies are presently underway both to ensure their longer-term integrity as well as their performance against currently circulating variants. Customers are encouraged to capitalize on this opportunity to stock up on FDA-approved COVID-19 Ag tests while supply remains available ahead of anticipated winter surges.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine